GSA Capital Partners’s X4 Pharmaceuticals XFOR Stock Holding History

GSA Capital Partners’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Buy	+76,314	New	+$313K	0.02%	1212
2025 Q3	–	Sell	-132,724	Closed	-$252K	–	2162
2025 Q2	$252K	Buy	+132,724	New	+$543K	0.02%	1375
2025 Q1	–	Sell	-42,455	Closed	-$934K	–	2134
2024 Q4	$934K	Buy	42,455 +25,532	+151%	+$407K	0.07%	452
2024 Q3	$340K	Buy	+16,923	New	+$353K	0.03%	1163
2024 Q2	–	Sell	-10,701	Closed	-$446K	–	2080
2024 Q1	$446K	Sell	10,701 -20,805	-66%	-$579K	0.04%	955
2023 Q4	$793K	Buy	31,506 +10,786	+52%	+$262K	0.07%	516
2023 Q3	$678K	Buy	+20,720	New	+$904K	0.06%	609

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's XFOR Position: Q2 2026 in Review

GSA Capital Partners opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 76,314 shares worth $356K. The stake represents 0.02% of the portfolio and ranks #1212 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in XFOR as recently as Q2 2025.

GSA Capital Partners first reported a position in XFOR in Q3 2023 and has held it in 7 quarters since. The position peaked at $934K in Q4 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

GSA Capital Partners held 76,314 shares of X4 Pharmaceuticals worth $356K as of Q2 2026.
X4 Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
X4 Pharmaceuticals made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1212 holding.
GSA Capital Partners first reported a position in X4 Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
GSA Capital Partners's X4 Pharmaceuticals position peaked at $934K in Q4 2024.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.